HKPD PE Ratio & Valuation, Is HKPD Overvalued

Historical Valuation

Cellyan Biotechnology Co Ltd (HKPD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Cellyan Biotechnology Co Ltd (HKPD) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：0.73

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Cellyan Biotechnology Co Ltd (HKPD) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Cellyan Biotechnology Co Ltd (HKPD) has a current Price-to-Book (P/B) ratio of 3.20. Compared to its 3-year average P/B ratio of 2.48, the current P/B ratio is approximately 29.01% higher. Relative to its 5-year average P/B ratio of 2.48, the current P/B ratio is about 29.01% higher. Cellyan Biotechnology Co Ltd (HKPD) has a Forward Free Cash Flow (FCF) yield of approximately 1.74%. Compared to its 3-year average FCF yield of 1.14%, the current FCF yield is approximately 52.73% lower. Relative to its 5-year average FCF yield of 1.14%, the current FCF yield is about 52.73% lower.

Performance Decomposition

AI Analysis

Market capitalization of HKPD increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of HKPD in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is HKPD currently overvalued or undervalued?

What is Cellyan Biotechnology Co Ltd (HKPD) fair value?

HKPD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Cellyan Biotechnology Co Ltd (HKPD) is between to according to relative valuation method.

How does HKPD's valuation metrics compare to the industry average?

The average P/S ratio for HKPD's competitors is 0.00, providing a benchmark for relative valuation. Cellyan Biotechnology Co Ltd Corp (HKPD) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for Cellyan Biotechnology Co Ltd (HKPD) as of Apr 19 2026?

As of Apr 19 2026, Cellyan Biotechnology Co Ltd (HKPD) has a P/B ratio of 3.20. This indicates that the market values HKPD at 3.20 times its book value.

What is the current FCF Yield for Cellyan Biotechnology Co Ltd (HKPD) as of Apr 19 2026?

As of Apr 19 2026, Cellyan Biotechnology Co Ltd (HKPD) has a FCF Yield of 1.74%. This means that for every dollar of Cellyan Biotechnology Co Ltd's market capitalization, the company generates 1.74 cents in free cash flow.

What is the current Forward P/E ratio for Cellyan Biotechnology Co Ltd (HKPD) as of Apr 19 2026?

As of Apr 19 2026, Cellyan Biotechnology Co Ltd (HKPD) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Cellyan Biotechnology Co Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Cellyan Biotechnology Co Ltd (HKPD) as of Apr 19 2026?

As of Apr 19 2026, Cellyan Biotechnology Co Ltd (HKPD) has a Forward P/S ratio of 0.00. This means the market is valuing HKPD at $0.00 for every dollar of expected revenue over the next 12 months.

HKPD Valuation